Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention
Information source: Sheba Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Edema; Cerebral Edema
Intervention: Tadalafil and acetazolamide (Drug); Acetazolamide (Drug)
Sponsored by: Sheba Medical Center
To evaluate the additive value of tadalafil given together with Diamox (acetazolamide) in
preventing acute mountain sickness in travelers to high altitude areas.
Official title: Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: Results will be evaluated by using the Lake Louise AMS scoring system
A randomized controlled study comparing:
Tadalafil [20mg x1/day] and acetazolamide [125mg x2 day], versus Acetazolamide [125mg x2
day] alone, in trekkers to altitude > 3,000 m.
Minimum age: 18 Years.
Maximum age: N/A.
- Participant in trekking to high altitude
- Agreement to sign the informed consent.
- No agreement to sign informed consent.
Locations and Contacts
Tel Hashomer, Israel
Center of Geographic Medicine, Tel Hashomer, Israel
Sheba Medical Ctr., Tel hashomer, Israel
Starting date: January 2006
Last updated: September 7, 2012